SCHEMBL11943822

SCHEMBL11943822

O=c1c(OC2CCCC2)c(N2CCN(Cc3ccccc3)CC2)cnn1-c1cccc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ SIGMAR1 Q99720 3/20 0.43
▸ HTR1A P08908 3/20 0.43
▸ HTR7 P34969 2/20 0.43
▸ POLB P06746 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ PPARG P37231 1/20 0.42
▸ NCOA2 Q15596 1/20 0.42
▸ NCOA1 Q15788 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ DRD2 P14416 2/20 0.42
▸ HTR2A P28223 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943817 0.90 CYP3A4 (0.46) LMNAALDH1A1KDM4EPKMSMN1; SMN2
SCHEMBL17058131 0.88 ALDH1A1 (0.42) LMNAALDH1A1KDM4EPKMSMN1; SMN2
SCHEMBL11943819 0.88 LMNA (0.42) LMNAALDH1A1KDM4EPKMSMN1; SMN2
SCHEMBL11943853 0.87 ALDH1A1 (0.49) ALDH1A1KDM4EPKMSMN1; SMN2HTR1A
SCHEMBL17058182 0.87 ALDH1A1 (0.41) LMNAALDH1A1KDM4EPKMSMN1; SMN2
SCHEMBL11943960 0.87 MAPT (0.51) ALDH1A1KDM4EPKMSMN1; SMN2POLB
SCHEMBL11943442 0.86 ALDH1A1 (0.42) LMNAALDH1A1KDM4ESMN1; SMN2HTR1A
SCHEMBL11945856 0.86 ALDH1A1 (0.46) LMNAALDH1A1KDM4EPKMSMN1; SMN2
SCHEMBL17058335 0.86 ALDH1A1 (0.48) ALDH1A1KDM4EPKMSMN1; SMN2HTR1A
SCHEMBL11945151 0.86 MAPT (0.50) ALDH1A1KDM4EPKMSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA LMNA 929/4885ALDH1A1 2437/4885KDM4E 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback